Viramune Affects Birth Control in HIV+ Women
March 31, 2000
The drug called Viramune (also known as nevirapine) appears to reduce the blood levels of the oral birth control pill Ortho-Novum, thereby reducing its effectiveness as a contraceptive. A recent study was conducted on HIV+ women who were taking both Viramune and Ortho-Novum. The women were all stable on the antiretroviral therapy, had CD4 counts above 100 upon entry, and undetectable viral loads below 400 copies.
In the study, women were initially given a birth control pill and were then checked for the blood levels of the birth control pill every hour for 36 hours. This was done to establish a "baseline" of the birth control drug levels. Once this baseline was established the women were started on Viramune following the drug company prescribed lead in regimen of 100 milligrams per day (one pill once a day) for 14 days, and were then increased to 200 milligrams (one pill twice a day).
Once they had reached the standard daily dosage of 200 milligrams of Viramune, blood samples were again checked for the drug level of Ortho-Novum present in the blood. What they found was that taking Viramune with Ortho-Novum lowered the level of the birth control drug in the blood increasing the risk of getting pregnant. To avoid unwanted pregnancies, women taking the oral contraceptive Ortho-Novum and who are on Viramune should consider using additional means of birth control (such as barriers like diaphragms.)
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.